IL157779A0 - Inhibitor of monoamine uptake - Google Patents

Inhibitor of monoamine uptake

Info

Publication number
IL157779A0
IL157779A0 IL15777902A IL15777902A IL157779A0 IL 157779 A0 IL157779 A0 IL 157779A0 IL 15777902 A IL15777902 A IL 15777902A IL 15777902 A IL15777902 A IL 15777902A IL 157779 A0 IL157779 A0 IL 157779A0
Authority
IL
Israel
Prior art keywords
inhibitor
monoamine uptake
monoamine
uptake
Prior art date
Application number
IL15777902A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23045157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL157779(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL157779A0 publication Critical patent/IL157779A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/48Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
IL15777902A 2001-03-06 2002-02-20 Inhibitor of monoamine uptake IL157779A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27373001P 2001-03-06 2001-03-06
PCT/US2002/003385 WO2002070457A1 (en) 2001-03-06 2002-02-20 Inhibitor of monoamine uptake

Publications (1)

Publication Number Publication Date
IL157779A0 true IL157779A0 (en) 2004-03-28

Family

ID=23045157

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15777902A IL157779A0 (en) 2001-03-06 2002-02-20 Inhibitor of monoamine uptake

Country Status (35)

Country Link
US (2) US20040082666A1 (hu)
EP (1) EP1379492B1 (hu)
JP (1) JP2004525912A (hu)
KR (1) KR20030092012A (hu)
CN (1) CN1229331C (hu)
AP (1) AP2003002855A0 (hu)
AT (2) AT414238B (hu)
AU (1) AU2002245385B2 (hu)
BR (1) BR0207716A (hu)
CA (1) CA2440161A1 (hu)
CH (1) CH695982A5 (hu)
CZ (1) CZ20032380A3 (hu)
DE (1) DE60226715D1 (hu)
DK (1) DK200301267A (hu)
EA (1) EA005768B1 (hu)
EC (1) ECSP034760A (hu)
EE (1) EE200300419A (hu)
ES (2) ES2201942B2 (hu)
FI (1) FI20031191A (hu)
GB (1) GB2389851B (hu)
HR (1) HRP20030710A2 (hu)
HU (1) HUP0303341A3 (hu)
IL (1) IL157779A0 (hu)
LT (1) LT5143B (hu)
LU (1) LU91038B1 (hu)
LV (1) LV13119B (hu)
NO (1) NO20033921L (hu)
NZ (1) NZ527431A (hu)
OA (1) OA12494A (hu)
PL (1) PL363840A1 (hu)
SE (1) SE526598C2 (hu)
SK (1) SK10632003A3 (hu)
TR (1) TR200705146T1 (hu)
WO (1) WO2002070457A1 (hu)
ZA (1) ZA200306882B (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0303341A3 (en) * 2001-03-06 2007-03-28 Lilly Co Eli Inhibitor of monoamine uptake and pharmaceutical compositions containing it
WO2005020976A2 (en) * 2003-08-27 2005-03-10 Eli Lilly And Company Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
CA2548304A1 (en) * 2003-12-12 2005-07-07 Eli Lilly And Company Selective norepinephrine reuptake inhibitors for the treatment of hot flashes, impulse control disorders and personality change due to a general medical condition
WO2011027359A2 (en) * 2009-07-30 2011-03-10 Matrix Laboratories Ltd Novel process for the preparation of 4-hydroxy atomoxetine
WO2012020418A1 (en) 2010-08-12 2012-02-16 Matrix Laboratories Ltd Novel polymorphs of 4-hydroxy atomoxetine hydrochloride
DE102013022397A1 (de) 2013-12-19 2016-07-07 Metrax Gmbh Vorrichtung zur Unterstützung eines Ersthelfers bei der Herzdruckmassage
GR1008819B (el) 2015-05-22 2016-08-01 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα που περιλαμβανει ατομοξετινη και μεθοδος παρασκευης αυτου
CN107935848B (zh) * 2017-11-21 2020-12-22 中国农业科学院兰州畜牧与兽药研究所 一种六茜素衍生物及其制备方法和应用
MX2021004883A (es) * 2018-10-31 2021-08-05 Apnimed Inc Delaware Metodos y composiciones para tratar apnea del sue?o.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018895A (en) 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4194009A (en) 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
FR2432500A1 (fr) * 1978-02-24 1980-02-29 Roussel Uclaf Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre de medicaments
US5112619A (en) * 1985-11-12 1992-05-12 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulation
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
ZA885824B (en) * 1987-08-14 1989-04-26 Merrell Dow Pharma Novel antidepressants
PH30083A (en) * 1991-02-25 1996-12-27 Lilly Co Eli Treatment of lower urinary tract disorders
TW514634B (en) 1997-10-14 2002-12-21 Lilly Co Eli Process to make chiral compounds
WO2000058262A1 (en) 1999-03-29 2000-10-05 Eli Lilly And Company Stereospecific method for preparing tomoxetine and intermediates thereof
DK1171417T3 (da) 1999-04-09 2006-02-20 Lilly Co Eli Fremgangsmåde til fremstilling af 3-aryloxy-3-arylpropylaminer og mellemprodukter deraf
EA200300567A1 (ru) * 2000-11-15 2004-10-28 Эли Лилли Энд Компани Лечение состояний тревоги
HUP0303341A3 (en) * 2001-03-06 2007-03-28 Lilly Co Eli Inhibitor of monoamine uptake and pharmaceutical compositions containing it

Also Published As

Publication number Publication date
JP2004525912A (ja) 2004-08-26
HUP0303341A2 (hu) 2004-01-28
ATE396170T1 (de) 2008-06-15
NZ527431A (en) 2005-05-27
GB2389851B (en) 2005-05-25
ECSP034760A (es) 2003-10-28
US7384983B2 (en) 2008-06-10
TR200705146T1 (tr) 2008-02-21
SE526598C2 (sv) 2005-10-18
LT5143B (lt) 2004-06-25
LV13119B (en) 2004-06-20
SK10632003A3 (sk) 2004-06-08
EE200300419A (et) 2004-02-16
ES2201942B2 (es) 2004-12-16
GB0323169D0 (en) 2003-11-05
AP2003002855A0 (en) 2003-08-20
EP1379492B1 (en) 2008-05-21
DK200301267A (da) 2003-11-06
PL363840A1 (en) 2004-11-29
NO20033921L (no) 2003-11-05
CN1494526A (zh) 2004-05-05
SE0302361L (sv) 2003-09-03
ES2305221T3 (es) 2008-11-01
WO2002070457A1 (en) 2002-09-12
US20040082666A1 (en) 2004-04-29
LU91038B1 (fr) 2003-09-11
CZ20032380A3 (en) 2004-03-17
CH695982A5 (de) 2006-11-15
US20050209341A1 (en) 2005-09-22
LT2003075A (en) 2004-03-25
ZA200306882B (en) 2004-12-03
EP1379492A1 (en) 2004-01-14
FI20031191A (fi) 2003-08-25
AU2002245385B2 (en) 2007-01-18
GB2389851A (en) 2003-12-24
HUP0303341A3 (en) 2007-03-28
NO20033921D0 (no) 2003-09-04
DE60226715D1 (de) 2008-07-03
CN1229331C (zh) 2005-11-30
AT414238B (de) 2006-10-15
ATA90422002A (de) 2006-01-15
ES2201942A1 (es) 2004-03-16
OA12494A (en) 2006-05-24
EA200300978A1 (ru) 2004-02-26
BR0207716A (pt) 2004-03-23
KR20030092012A (ko) 2003-12-03
SE0302361D0 (sv) 2003-09-03
WO2002070457A8 (en) 2004-06-03
HRP20030710A2 (en) 2004-08-31
EA005768B1 (ru) 2005-06-30
CA2440161A1 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
HUP0600294A2 (en) Skin-permeable selective cyclooxygenase-2 inhibitor composition
GB0125445D0 (en) Protease Inhibitors
HK1071886A1 (en) Novel compounds and compositions as cathepsin inhibitors
HK1060121A1 (en) Metalloproteinase inhibitors
IL159125A0 (en) Novel compounds and compositions as cathepsin inhibitors
AU2003290735A8 (en) Inhibitors of monoamine uptake
GB2389851B (en) Inhibitor of monoamine uptake
GB2380200B (en) Photoluminescent compounds
AU2002360673A8 (en) Gp41 inhibitor
SG119168A1 (en) Utilization of at least one aminopeptidase inhibitor
EP1401453A4 (en) PROTEASE INHIBITORS
EP1364653A4 (en) CASOASE-3 INHIBITORS
HUP0303185A3 (en) Glyt-1 inhibitors
GB0228482D0 (en) Inhibitors of monoamine uptake
EP1391198A4 (en) NEW INHIBITOR OF SPHINGOLIPID SYNTHESIS
GB0314414D0 (en) Inhibitors of monoamine uptake
GB0128453D0 (en) Inhibitors
GB0101135D0 (en) Inhibitors
GB0101134D0 (en) Inhibitors
IL159135A0 (en) Novel compounds and compositions as cathepsin inhibitors
GB0100485D0 (en) Corrosion inhibitors
GB0121073D0 (en) Inhibitors of complement activation
GB0210428D0 (en) Calmag JG - magnetic in-line pushfit scale inhibitor
GB0210427D0 (en) Calmag - magnetic in-line scale inhibitor
GB0210426D0 (en) Caltronic - electronic scale inhibitor